Anne Wojcicki's nonprofit gets court approval to buy 23andMe for $305 million

Anne Wojcicki's nonprofit, TTAM Research Institute, has received court approval to acquire the bankrupt genetic testing firm 23andMe for $305 million, outbidding Regeneron Pharmaceuticals. This transaction, set to close in the coming weeks, will transfer "substantially all" of 23andMe's assets, including its core Personal Genome Service and Lemonaid Health subsidiary. The acquisition marks the culmination of Wojcicki's efforts to take the company private, ending its tumultuous public tenure since its 2021 IPO, which was characterized by financial struggles and significant privacy concerns, and aims to operate the firm outside market pressures.

Analysis

The acquisition of 23andMe's assets by co-founder Anne Wojcicki's nonprofit, TTAM Research Institute, for $305 million marks the conclusion of the company's tumultuous tenure as a public entity. This transaction, approved through a Chapter 11 bankruptcy process, saw TTAM outbid Regeneron Pharmaceuticals' $256 million offer, indicating competitive interest in the company's core assets. The deal fulfills Wojcicki's long-held objective to operate the company privately, away from market pressures that have been present since its 2021 public listing. This move follows a period of significant internal strife, highlighted by the resignation of all independent directors in late 2023 over strategic disagreements with Wojcicki. The acquisition includes not only the primary genetic testing service but also the Lemonaid Health subsidiary, which 23andMe had previously intended to close, suggesting a potential re-evaluation of its strategic value. However, significant headwinds remain, as the transfer of data for approximately 13 million customers occurs against a backdrop of heightened privacy concerns, stemming from events like the 2023 data breach.

Key Decisions for Investors

• For investors in Regeneron (REGN), the failed bid is a minor setback but confirms a strategic interest in genetic data assets; monitor for subsequent M&A activity in this space as the company may seek alternative targets.
• The failure of 23andMe as a public company serves as a cautionary signal for the broader consumer genomics sector, highlighting persistent challenges in achieving profitability and the critical importance of a viable business model beyond initial user acquisition.
• This event underscores data privacy and governance as material risks, and investors should intensify scrutiny of data security protocols and potential liabilities for any company managing large-scale sensitive consumer information, especially within the tech and healthcare sectors.